IPF Research

See below for the latest in research news related to Idiopathic Pulmonary Fibrosis (IPF). This is where the PFF will share relevant news articles, press releases, and study results in the field of IPF.

Bellerophon Therapeutics Announces Publication of Cohort 1 of iNO-PF Phase 2/3 Study in the CHEST Journal and Participation in Webinar to Discuss Clinical Results
- by Kelsey Overberg
- Sep 23, 2020
Full story: Bellerophon Therapeutics Announces Publication of Cohort 1 of iNO-PF Phase 2/3 Study in the CHEST Journal and Participation in Webinar to Discuss Clinical Results
Primary endpoint achieved with ziritaxestat in NOVESA trial in systemic sclerosis patients
- by Kelsey Overberg
- Sep 16, 2020
Full story: Primary endpoint achieved with ziritaxestat in NOVESA trial in systemic sclerosis patients
Bellerophon Therapeutics Announces First Patient Treated in Phase 3 Clinical Study of INOpulse® Inhaled Nitric Oxide Therapy for COVID-19
- by Kelsey Overberg
- Sep 15, 2020
Full story: Bellerophon Therapeutics Announces First Patient Treated in Phase 3 Clinical Study of INOpulse® Inhaled Nitric Oxide Therapy for COVID-19
FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19
- by Kelsey Overberg
- Sep 15, 2020
Full story: FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19
Pfizer and BioNTech share positive early data on lead mRNA vaccine candidate BNT162B2 against COVID-19
- by Kelsey Overberg
- Sep 15, 2020
Full story: Pfizer and BioNTech share positive early data on lead mRNA vaccine candidate BNT162B2 against COVID-19
Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial
- by Kelsey Overberg
- Sep 15, 2020
Full story: Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial
Galecto, Inc. Receives U.S. and EU Orphan Drug Designations for GB0139 in Idiopathic Pulmonary Fibrosis
- by Kelsey Overberg
- Sep 1, 2020
Full story: Galecto, Inc. Receives U.S. and EU Orphan Drug Designations for GB0139 in Idiopathic Pulmonary Fibrosis
Development of COVID-19 vaccine AZD1222 expands into US Phase III clinical trial across all adult age groups
- by Kelsey Overberg
- Sep 1, 2020
Full story: Development of COVID-19 vaccine AZD1222 expands into US Phase III clinical trial across all adult age groups
Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Phase 1 Study of Its mRNA Vaccine Against COVID-19 (mRNA-1273)
- by Kelsey Overberg
- Jul 17, 2020
Full story: Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Phase 1 Study of Its mRNA Vaccine Against COVID-19 (mRNA-1273)
NIH Awards Major Grant In Pulmonary Fibrosis Research
- by Kelsey Overberg
- Jul 17, 2020
Full story: NIH Awards Major Grant In Pulmonary Fibrosis Research
Galecto Advances Phase 2b Study of GB0139 in Idiopathic Pulmonary Fibrosis; Recruitment Remains on Track Despite COVID-19 Crisis
- by Kelsey Overberg
- May 12, 2020
Full story: Galecto Advances Phase 2b Study of GB0139 in Idiopathic Pulmonary Fibrosis; Recruitment Remains on Track Despite COVID-19 Crisis
I-Mab Announces IND Clearance from FDA for TJM2 to Treat Cytokine Release Syndrome (CRS) Associated with Severe Coronavirus Disease 19 (COVID-19)
- by Kelsey Overberg
- Apr 17, 2020
Full story: I-Mab Announces IND Clearance from FDA for TJM2 to Treat Cytokine Release Syndrome (CRS) Associated with Severe Coronavirus Disease 19 (COVID-19)
FDA GRANTS CALCIMEDICA PERMISSION TO BEGIN DOSING CM4620-IE IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA UNDER A NEWLY OPENED IND
- by Kelsey Overberg
- Apr 17, 2020
Full story: FDA GRANTS CALCIMEDICA PERMISSION TO BEGIN DOSING CM4620-IE IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA UNDER A NEWLY OPENED IND
How a 100-year-old vaccine for tuberculosis could help fight the novel coronavirus
- by Kelsey Overberg
- Apr 17, 2020
Full story: How a 100-year-old vaccine for tuberculosis could help fight the novel coronavirus
Novant Health Initiates Phase 2 COVID-19 Trial with CytoDyn’s Leronlimab
- by Kelsey Overberg
- Apr 13, 2020
Full story: Novant Health Initiates Phase 2 COVID-19 Trial with CytoDyn’s Leronlimab
INOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Today
- by Kelsey Overberg
- Apr 13, 2020
Full story: INOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Today
Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy
- by Kelsey Overberg
- Apr 13, 2020
Full story: Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy
Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19
- by Kelsey Overberg
- Mar 31, 2020
Full story: Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19
Investigational COVID-19 Convalescent Plasma - Emergency INDs
- by Kelsey Overberg
- Mar 31, 2020
Full story: Investigational COVID-19 Convalescent Plasma - Emergency INDs
FDA grants IND “Study May Proceed” for COVID-19 trial to NeuroRx, Inc. in partnership with RELIEF THERAPEUTICS (SIX:RLF) for treatment of Acute Respiratory Distress
- by Kelsey Overberg
- Mar 31, 2020
Full story: FDA grants IND “Study May Proceed” for COVID-19 trial to NeuroRx, Inc. in partnership with RELIEF THERAPEUTICS (SIX:RLF) for treatment of Acute Respiratory Distress

Book a PFF Ambassador for your event. Call 844.TalkPFF >

Life with PF

Our Role

Get Involved

Ways to Give

Medical Community

Sponsors and Exhibitors

The Pulmonary Fibrosis Foundation rates among top charities in the U.S. The PFF has a three-star rating from Charity Navigator and is a Better Business Bureau accredited charity. The Foundation has met all of the requirements of the National Health Council Standards of Excellence Certification Program®.

PRIVACY POLICY TERMS OF USE

© 2019 Pulmonary Fibrosis Foundation | 230 East Ohio Street, Suite 500, Chicago, Illinois 60611

p. 888.733.6741 | f. 866.587.9158 | info@pulmonaryfibrosis.org

Join Our Monthly eNewsletter

PRIVACY POLICY TERMS OF USE

© 2019 Pulmonary Fibrosis Foundation | 230 East Ohio Street, Suite 500, Chicago, Illinois 60611

p. 888.733.6741 | f. 866.587.9158 | info@pulmonaryfibrosis.org

Join Our Monthly eNewsletter
Subscribe to receive the most current news and updates from the Pulmonary Fibrosis Foundation.